Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high ‐risk neuroblastoma

ConclusionThe combination of bortezomib and irinotecan was well tolerated by patients with relapsed/refractory NBL with favorable toxicity profile. It also showed modest but promising clinical activity and merits further testing in Phase II studies.

Source: Pediatric Blood and Cancer - April 24, 2017 Category: Cancer & Oncology Authors: Rajen Mody, Lili Zhao, Gregory Anthony Yanik, Valerie Opipari Tags: RESEARCH ARTICLE Source Type: research